Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 9/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208041 | 0.86 | PPARG (0.53) | ALDH1A1TDP1PPARGPTGER1LMNA | |
| SCHEMBL5119912 | 0.83 | PPARG (0.42) | ALDH1A1TDP1PPARGPTGER1KDM4E | |
| SCHEMBL5112614 | 0.82 | PPARG (0.62) | PPARG | |
| SCHEMBL5120054 | 0.82 | KDM4E (0.44) | ALDH1A1PPARGPTGER1POLBKDM4E | |
| SCHEMBL5105836 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TDP1PPARGLMNAPOLB | |
| SCHEMBL5113810 | 0.80 | PPARG (0.47) | ALDH1A1PPARGLMNAPOLBKDM4E | |
| SCHEMBL5111582 | 0.78 | PPARG (0.41) | ALDH1A1PPARGPTGER1PTGDR2KDM4E | |
| SCHEMBL3212765 | 0.78 | PPARG (0.68) | PPARG | |
| SCHEMBL5120924 | 0.77 | PPARG (0.64) | PPARG | |
| SCHEMBL5119845 | 0.77 | PPARG (0.64) | PPARGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | ALDH1A1 1527/4885TDP1 4792/4885PPARG 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.